BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang HN, Thorpe R, Knezevic I, Casas Levano M, Chilufya MB, Chirachanakul P, Chua HM, Dalili D, Foo F, Gao K, Habahbeh S, Hamel H, Kim GH, Perez Rodriguez V, Putri DE, Rodgers J, Savkina M, Semeniuk O, Srivastava S, Tavares Neto J, Wadhwa M, Yamaguchi T. Regulatory challenges with biosimilars: an update from 20 countries. Ann N Y Acad Sci 2021;1491:42-59. [PMID: 33222245 DOI: 10.1111/nyas.14522] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sheth S, Vashishta L, Goyal R, Rathore A, Chirmule N. On the Manufacturers of Biosimilars in Asia. Clin Pharmacol Ther 2022. [PMID: 36199234 DOI: 10.1002/cpt.2750] [Reference Citation Analysis]
2 Chai Q, Wen H, Lang Y, Zhang L, Song Y, Liu X. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China. Clin Drug Investig. [DOI: 10.1007/s40261-022-01197-9] [Reference Citation Analysis]
3 Manzi L, Sepe N, Migliaccio W, Lanzoni L, Iozzino L, D'Angelo F, Colarusso L, Montenegro S, Palmese A, D'Hooghe T, Ulloa-Aguirre A, Koloda Y, Lispi M. Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions. Int J Mol Sci 2022;23:6762. [PMID: 35743204 DOI: 10.3390/ijms23126762] [Reference Citation Analysis]
4 Yang J, Lin L, Long Q, Zhang Q, Sun G, Zhou L, Wang Q, Zhu J, Li F, Hu W. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. BioDrugs 2022. [PMID: 35594017 DOI: 10.1007/s40259-022-00534-w] [Reference Citation Analysis]
5 Wadhwa M, Kang H, Thorpe R, Knezevic I, Aprea P, Bielsky M, Ekman N, Heim H, Joung J, Kurki P, Lacana E, Njue C, Nkansah E, Savkina M, Thorpe R, Yamaguchi T, Wadhwa M, Wang J, Weise M, Wolff-holz E, Allam M, Bahaa H, Sayed M, Al-oballi A, Alshahrani A, Baek D, Kim J, Chua H, Gangakhedkar J, Jagtap MP, Lyaskovsky T, Okudaira S, Ondee W, Sotomayor P, Ricra JS, Uviase J, Ahmed F, Rajendran Y, Defendi HT, Cho SO, Qu A, Acha V, Gencoglu M, Ho K, Baldrighi M, Schiestl M, Watson K, Spitzer E, Chong S, Fukushima A, Kang H, Knezevic I, Pante G, Simao M. WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June – 2 July 2021. Biologicals 2022. [DOI: 10.1016/j.biologicals.2022.03.001] [Reference Citation Analysis]
6 Nupur N, Joshi S, Gulliarme D, Rathore AS. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms. Front Bioeng Biotechnol 2022;10:832059. [DOI: 10.3389/fbioe.2022.832059] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Munoz Tellez V. Bolar Exception. Access to Medicines and Vaccines 2022. [DOI: 10.1007/978-3-030-83114-1_5] [Reference Citation Analysis]
8 Jones HP, Vishwanatha JK, Krug EL, Harwood E, Boman KE, Unold T, Thorpe RJ. The Association Between NRMN STAR Grantsmanship Self-Efficacy and Grant Submission. Ethn Dis 2021;31:559-66. [PMID: 34720559 DOI: 10.18865/ed.31.4.559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rahalkar H, Sheppard A, Santos GML, Dasgupta C, Perez-Tapia SM, Lopez-Morales CA, Salek S. Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities. Front Med (Lausanne) 2021;8:726660. [PMID: 34568384 DOI: 10.3389/fmed.2021.726660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rahalkar H, Sheppard A, Salek S. Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices. Front Pharmacol 2021;12:711361. [PMID: 34434109 DOI: 10.3389/fphar.2021.711361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel) 2021;14:189. [PMID: 33669108 DOI: 10.3390/ph14030189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]